Sirolimus en la enfermedad de Gorham-Stout. Caso clinico.
Gorham-Stout disease (GSD), or essential osteolysis, is a rare disease characterized by the proliferation of vascular channels which leads to the destruction and resorption of bone mass. It has an unknown origin (1).
The first case published in the literature of "vanishing bone disease", as this condition is also known, was described by Jackson in 1838. In his study, the author described the progressive disappearance of a humerus (2). In 1955, Gorham et al., published a series with 24 cases of their own and other cases with similar clinical and histological characteristics (3). There are approximately 185 described cases with no differences regarding sex or a clear pattern of hereditary transmission. However, there is a predominant incidence of the disease during the first decades of life (1). The most common initial symptom is the finding of pathological fractures, but these cases are generally unspecific (4), and they can affect any part of the skeleton, although with a preference for flat bones, such as the jaw, ribs, shoulder and pelvis. Its histopathology is characterized by proliferation of small vessels or by lymph channels being replaced by benign fibrovascular tissue (1). It generally has a good prognosis, although pulmonary complications secondary to lesions of the thoracic skeleton accompanied by chylothorax and vertebral compromise are rare but fatal complications for this condition (5).
There is no clear consensus on the most adequate treatment. A medical approach (interferon alfa-2b and bisphosphonates are some of the most common choices), surgery to reduce the flow towards the pleural cavity (ligation of the thoracic duct, pleurodesis and pleurectomy), radiotherapy and chemotherapy (mainly bleomycin and cyclophosphamide) are options which have been tried in isolated cases with differing degrees of success (1).
We present a case of GSD complicated with pleural effusion in which clinical and radiological remission was achieved with a single lead dose of sirolimus 4 mg and maintenance doses of 1.5 mg/day afterwards.
The patient is a 43-year-old woman who was admitted with thoracic pain, dyspnea on slight exertion and tumor formation in the left hypochondrium. In her personal history she showed recurrent dislocations of the right shoulder and endometriosis which had been diagnosed two years before. One year before admission, she started showing mechanical pain on the sternal region together with inflammatory signs, without previous trauma. Six months prior to her admission, she presented progressive mechanical pain on the left side, together with formation of a tumor in the left hypochondrium which slowly increased in size, and progressive dyspnea which became dyspnea on slight exertion without hemoptysis, fever, feeling of dysthermia, chills, rigors or any other infectious or respiratory symptoms. She did not report weight loss, asthenia or anorexia. The examination revealed pain and thickening of the 10th left posterior rib arch, pain on palpation on the lower third portion of the sternal region, and diffuse tumor in the left hypochondrium with surface hematoma which was poorly delimited, soft and painless. On cardiopulmonary auscultation, the patient showed semiology of pleural effusion in the lower and middle regions of the left hemithorax. The analysis on admission revealed normal CBC and biochemistry values without elevation of acute-phase reactants. Table 1 shows the analytical data on admission.
The thoracic X-ray reveals pleural effusion which occupies two thirds of the left hemithorax and the left rib cage. Partial absence of the 6th left costal arch may be appreciated as wel l (Fig. 1).
Thoracentesis was performed for evacuation with output of serosanguineous fluid with the following analytical data: glucose 97 mg/dL, LDH 179 UI/L, erythrocytes 571,100/[micro]L, leukocytes 11,620/ [micro]L (3% polymorphonuclear, 97% mononuclear), proteins 5.3 g/dL, pH 7.43, rheumatoid factor 9.1 UI/mL, amylase 27 Ul/l, cholesterol 86 mg/dl, triglycerides 26 mg/dl, adenosine deaminase (ADA) 13 UI/L. Negative flow cytometry of the pleural fluid for lymphoid infiltration. Cytology of the fluid without cellular atypias. Cultures of the pleural fluid for bacteria, mycobacteria, parasites and fungi were negative. Also, the Mantoux test and the gamma interferon test with quantiferon-TB(r) were negative for latent tuberculosis infection. The serology tests for hepatotropic viruses and human immunodeficiency virus (HIV) were negative. The mammography and the gynecologic ultrasound were normal. Both the bone scintigraphy (Fig. 2) and the CT scan (Fig 3), thoracic MRI and PET revealed hypoplasia and an osteolytic lesion in the 10th and 6th left rib arches together with effusion, significant left pleural inflammation and involvement of adjacent soft parts.
A diagnostic thoracotomy was performed, and it showed important signs of inflammation and pleural hyperemia without signs of malignancy or granulomas. Samples of bone, pleura and pulmonary parenchyma were obtained. The histological results of the pleural and pulmonary tissue showed findings compatible with an unspecific inflammatory process. The rib biopsy revealed a chronic inflammatory process with mainly plasmacytoid infiltrate and granulation tissue with many artifacts due to decalcification. In view of these findings and the possibility of actinomycosis, empiric therapy was started with penicillin (doses of 6 million UI/6h for 4 weeks), pending the results of the polymerase chain reaction for Actinomices sp. Given the lack of improvement and the negative result of the PCR test, a new empiric therapy with prednisone was started at a dose of 1 mg/kg/day. In spite of these treatments and the placement of a pleural drain, the patient presented recurring pleural effusion, which in the last occasion was bilateral, with right predominance and larger abdominal tumor formation. The vascular endothelial growth factor (VEGF) was measured and it showed elevated levels (287 pg/mL, normal range 0-128.9 pg/mL). At this stage, the case was reviewed again in view of the clinical, analytical and radiological findings, and although the initial histological results were not compatible, a diagnosis of GSD was made and it was decided to start treatment with sirolimus after the patient signed her informed consent. The therapy was administered initially with a single dose of 4 mg (lead dose), and afterwards at a rate of 1.5 mg/day. The response was very satisfactory from the beginning, with disappearance of the symptoms of dyspnea, pain and abdominal tumor formation. The treatment was maintained over 10 months, with sirolimus levels slightly below the limits established by the laboratory (3.8-4.3 ng/ mL; threshold: 4 ng/mL minimum and 10 ng/mL maximum), which were monitored every two months. However, due to the suspicion of a relationship between the administration of sirolimus and episodes of abundant metrorrhagia, the treatment was suspended. A few days later, dyspnea, rib pain and particularly the abdominal tumor formation reappeared. The treatment with sirolimus was restarted, with completer remission at the 4th week and normal menstruation. Then, after a reassessment of the biopsy and particularly of the bone samples from the rib arch with immunohistochemical techniques, areas of lymphatic vascular proliferation were observed with D2-40 monoclonal antibody (useful as a specific marker of lymphatic vessels), compatible with the diagnosis of GSD. Since then, and two years after the onset of the symptoms and the analytical and radiological monitoring, the patient is asymptomatic, without changes in the complementary tests.
In GSD, massive and progressive osteolysis is caused by the abnormal proliferation of endothelial capillaries with vascular or lymphatic origin. Although the mechanism of resorption is not known, some researchers have found an increased activity of osteoclasts (6,7) together with an associated elevation in VEGF and, in other cases, with increased levels of interleukin (6). In our case, we observed elevated VEGF levels which might be used during monitoring and which correlated with the symptoms of the patient. GSD is considered a diagnosis of exclusion, with clinical, radiological and histopathological findings in absence of a hereditary, metabolic, neoplastic, immunological or infectious cause, and in most cases there are no laboratory findings (8). From a radiological perspective, the first changes are similar to those found in osteoporosis. A MR image shows disappearance of the bone morphology and areas with increased or reduced enhancement, which may represent different stages of hemorrhage (9). In our patient, a diagnosis was reached through clinical and radiological findings with images compatible with lytic lesions, after a reasonable elimination of other pathologies with a neoplastic, infectious, inflammatory or metabolic origin, and also thanks to compatible histopathological findings. Although there are some diagnostic criteria (10), they are very rarely used by the authors in the literature for diagnosis, and many of them only use them to reach a diagnosis of exclusion in an adequate clinical context (1,11,12).
Some of the main GSD complications are chylothorax and, less commonly, serosanguineous pleural effusion. These complications are associated with an increase in mortality (13).
There are surgical, radiotherapeutic and medical treatments available. This last category includes mainly octreotide, bevacizumab, propranolol, interferon alfa-2b and bisphosphonates (these two last drugs are the most commonly used ones, either independently or combined). They all show disparate individual results, and for this reason none of them has been established as a standard treatment given the lack of studies on this pathology. Sirolimus is indicated to prevent rejection in transplanted patients, and its mechanism of action inhibits the FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), which causes a decrease in protein synthesis and, consequently, in cellular proliferation and angiogenesis (14). In this regard, a therapeutic alternative has been essayed recently with sirolimus in pediatric patients with vascular and lymphatic anomalies, including GSD, due to its antiangiogenic activity, with excellent results (14). Also, a clinical essay is currently being carried out with this group of patients, with significant preliminary results. For this reason, it was prescribed in our case (1,15). It is worth pointing out that sirolimus was administered at low doses with good clinical response, in spite of the fact that sometimes the registered levels were below the minimum threshold suggested by the laboratory (4 ng/mL), unlike the other two cases published in the literature, one with pleural effusion (with levels around 9-12 mcg/L) (16) and the other with bone involvement exclusively (10-15 ng/mL) (17). Some of the most common secondary effects are: infections (fungal, viral, bacterial or caused by Herpes simplex), thrombocytopenia, anemia, leukopenia, hypocalcemia, hypophosphatemia, diabetes, hypertension, menstrual disorders, liver and kidney alterations, and increased risk of cancer, mainly lymphoma and skin cancer (14,15). In our case, the patient showed metrorrhagia, a symptom which did not reappear when the treatment was reintroduced. To date, the patient has not presented any other secondary effect.
Finally, the recurrence of symptoms after the treatment was suspended and the clinical response after the reintroduction of sirolimus reveal a significant role in the control of GSD in this particular case.
Received: 17 July 2016
Revised: 21 August 2016
Accepted: 25 November 2016
Conflict of interest: nothing
To Dr. Maria Dolores Ludena De La Cruz of the Pathology Department of the for their contributions in the histopathological findings. To Dr. Leticia Moralejo and Professor F Javier Laso of the Internal Medicine Service of the Hospital Universitario de Salamanca for his contribution in the diagnosis and follow-up of the patient.
(1.) Dellinger MT, Garg N, Olsen BR. Viewpoints on vessels and vanishing bones in Gorham-Stout disease. Bone. 2014; 63: 47-52.
(2.) Jackson JB. A boneless arm. Boston Med Surg J. 1838; 18: 368-9.
(3.) Gorham LW, Stout AP. Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis. J Bone Joint Surg Am. 1955; 37-A: 985-1004.
(4.) Choma ND, Biscotti CV, Bauer TW, Mehta AC, Licata AA. Gorham's syndrome a case report and review of the literature. Am J Med. 1987; 83: 1151-6.
(5.) Johnson PM, McClure JG. Observations on massive osteolysis; a review of the literature and report of a case. Radiology. 1958; 71: 28-42.
(6.) Moller G, Priemel M, Amling M, Werner M, Kuhlmey AS, Delling G. The Gorham-Stout syndrome (Gorham's massive osteolysis) A report of six cases with histopathological findings. J Bone Joint Surg Br. 1999; 81: 501-6.
(7.) Tie ML, Poland GA, Rosenow 3rd EC. Chylothorax in Gorham's syndrome A common complication of a rare disease. Chest. 1994; 105: 208-13.
(8.) Collins J. Case 92 Gorham syndrome. Radiology. 2006; 238: 1066-69.
(9.) Dominguez R, Washowich TL. Gorham's disease or vanishing bone disease plain film, CT, and MRI findings of two cases. Pediatr Radiol. 1994; 24: 316-8.
(10.) Heffez L, Doku HC, Carter BL, Feeney JE. Perspectives on massive osteolysis Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol. 1983; 55: 331-43.
(11.) Ayuso-Velasco R, Lopez-Gutierrez JC. Mortalidad en pacientes con osteolisis de origen linfatico. Revision de 54 casos. An Pediatr (Barc). 2012; 77: 83-7.
(12.) Nikolaou VS, Chytas D, Korres D, Efstathopoulos N. Vanishing bone disease (Gorham-Stout syndrome) A review of a rare entity. World J Orthop. 2014; 5: 694-8.
(13.) Chavanis N, Chaffanjon P, Frey G, Vottero G, Brichon PY. Chylothorax complicating Gorham's disease. Ann Thorac Surg. 2001; 72: 937-9.
(14.) Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011; 57: 1018-24.
(15.) Adams DM, Trenor 3rd CC, Hammill AM, Vinks AA, Patel MN, Chaudry G. Efficacy and safety of Sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016; 137: e20153257.
(16.) Cramer SL, Wei S, Merrow AC, Pressey JG. Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy. J Pediatr Hematol Oncol. 2016; 38: e129.
(17.) Nozawa A, Ozeki M, Kuze B, Asano T, Matsuoka K, Fukao T. Gorham-Stout Disease of the Skull Base With Hearing Loss Dramatic Recovery and Antiangiogenic Therapy. Pediatr Blood Cancer. 2016; 63:931-934
Vanessa Garcia , Gloria Alonso-Claudio , M-Teresa Gomez-Hernandez , Antonio-J Chamorro 
 Departamento de Medicina Interna. Hospital Clinico Universitario de Salamanca. Salamanca. Espana.
 Departamento de Cirugia Toracica. Hospital Clinico Universitario de Salamanca. Salamanca. Espana
Antonio Chamorro. Departamento de Medicina Interna. Hospital Clinico Universitario de Salamanca, Paseo San Vicente 58-182 C.P 37007 Salamanca. Espana. Email: email@example.com
Caption: Figure 1. X-ray of left rib cage which may show partial disappearance of the 6th left lateral and anterior rib arch.
Caption: Figure 2. Bone scintigraphy reveals partial absence of the 10th left posterior rib arch.
Caption: Figure 3. Positron emission tomography. A. shown the absence of the 6th and B. 10th left ribs arches.
Table 1. Analysis on admission of patient. Parameter Value Glucose 98 mg/dL Urea 32 mg/dL Creatinine 0.63 mg/dL Total bilirubin 0.56 mg/dL Proteins 7.5 g/dL Albumin 4.7 g/dL Hemoglobin 11.9 gr/dL Fibrinogen 400 mg/dL C-reactive protein 1.50 mg/dL Osmolarity 267 m0smol/kg. Aspartate Transaminase (AST) 20 UI/L Alanine Transaminase (ALT) 17 UI/L Alkaline phosphatase (ALP) 63 UI/L Gamma-glutamyltransferase (GGT) 21 UI/L Lactate dehydrogenase (LDH) 157 UI/L Erythrocyte sedimentation rate (ESR) 27 mm Prothrombin time 98% Hematocrit 34.5% Leukocytes 6.38 x [10.sup.3]/[micro]L Platelets 456 x [10.sup.3]/[micro]L Activated Partial Thromboplastin Time 29.5 s INR 1.01
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Case report|
|Author:||Garcia, Vanessa; Alonso-Claudio, Gloria; Gomez-Hernandez, M-Teresa; Chamorro, Antonio-J|
|Date:||Oct 1, 2016|
|Previous Article:||Tratamiento de la enfermedad linfoproliferativa post-trasplante renal con rituximab y conversion a inhibidor m-TOR.|
|Next Article:||Inmunoterapia beta-amiloide: ?la esperanza para la enfermedad de alzheimer?|